VWR Corporation (NASDAQ:VWR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The brokerage currently has a $37.00 price target on the medical research company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.78% from the company’s previous close.
According to Zacks, “VWR’s second-quarter earnings report was quite impressive, with both the top and the bottom line beating the Zacks Consensus Estimate. Geographically, the company recorded growth in Americas during the reported quarter driven by strong sales of equipment and instrumentation. Management is also looking forward to the long-term synergy benefits from the proposed merger with Avantor. The merger is expected to strengthen VWR’s business across the Americas and Europe. While we await the merger to close in the fourth quarter of 2017 we note that the stock price has already reached close to Avantor’s offer price and hence the short-term upside potential of VWR is limited now. On the flip side, a drop in EMEA-APAC sales was disappointing. Moreover, foreign currency was a major dampener. VWR’s poor margin scenario also raises concern.”
Several other equities analysts also recently commented on VWR. William Blair downgraded shares of VWR Corporation from an “outperform” rating to a “market perform” rating in a research note on Monday, May 15th. BidaskClub downgraded shares of VWR Corporation from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 27th. Finally, ValuEngine raised shares of VWR Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. VWR Corporation has an average rating of “Hold” and an average price target of $31.67.
VWR Corporation (NASDAQ VWR) traded down 0.06% on Tuesday, hitting $33.08. 125,071 shares of the stock were exchanged. The company has a market capitalization of $4.36 billion, a PE ratio of 30.63 and a beta of 1.19. VWR Corporation has a 1-year low of $24.42 and a 1-year high of $37.25. The company has a 50-day moving average price of $33.01 and a 200 day moving average price of $31.24.
VWR Corporation (NASDAQ:VWR) last posted its quarterly earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.45 by $0.04. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.16 billion. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter last year, the business posted $0.42 EPS. Analysts anticipate that VWR Corporation will post $1.87 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was first published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/09/12/vwr-corporation-vwr-upgraded-to-buy-by-zacks-investment-research.html.
Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in VWR Corporation by 79.2% in the 1st quarter. JPMorgan Chase & Co. now owns 4,531,105 shares of the medical research company’s stock valued at $127,777,000 after purchasing an additional 2,002,306 shares during the last quarter. US Bancorp DE lifted its stake in VWR Corporation by 6.4% in the 1st quarter. US Bancorp DE now owns 55,764 shares of the medical research company’s stock valued at $1,573,000 after purchasing an additional 3,354 shares during the last quarter. Shapiro Capital Management LLC bought a new position in VWR Corporation in the 1st quarter valued at approximately $66,793,000. Earnest Partners LLC lifted its stake in VWR Corporation by 116.8% in the 1st quarter. Earnest Partners LLC now owns 1,797,102 shares of the medical research company’s stock valued at $50,678,000 after purchasing an additional 968,313 shares during the last quarter. Finally, 1st Global Advisors Inc. lifted its stake in VWR Corporation by 17.3% in the 1st quarter. 1st Global Advisors Inc. now owns 11,289 shares of the medical research company’s stock valued at $318,000 after purchasing an additional 1,664 shares during the last quarter.
About VWR Corporation
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.